ClinicalTrials.gg
CompletedNCT01498068Updated Jan 30, 2015Results posted

Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C

A Phase 3 interventional study of Telaprevir and Pegylated-interferon-alfa-2a in Genotype 1 Chronic Hepatitis C, sponsored by Janssen-Cilag International NV. Completed at 5 sites in Russian Federation. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-01-30.

Sponsored by Janssen-Cilag International NV (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing telaprevir in Hepatitis C — none open to participants now, none under way, none of them phase 3. telaprevir · Hepatitis C.

Enrollment
17th of 39
36 · median 30
Started
2012
with 11 others
Phase 3
13 of 39
none open now
Registered
24th of 39
by date
Lead sponsor
4 of 39
Janssen-Cilag International NV

Among the 39 studies testing telaprevir in Hepatitis C, this one is the 17th largest by enrollment, is one of 12 that started in 2012, is one of 13 in phase 3, and was the 24th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

None of the 39 studies testing telaprevir in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →

About telaprevir

telaprevir: first FDA approval 2011 (INCIVEK), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing telaprevir in Hepatitis C as a file.
02

Study summary

The purpose of this study is to determine the effectiveness, safety and tolerability of telaprevir administered as 750 mg every 8 hours (q8h) in combination with pegylated interferon (Peg-IFN)-alfa-2a and ribavirin (RBV) in treatment-naïve and treatment-experienced Russian participants with genotype 1 chronic hepatitis C.

Read the detailed description

This is an open-label (all persons know the study drug assignment), multicenter study in treatment-naïve (participant did not receive any previous treatment for the treatment of hepatitis C) and treatment-experienced (participant did receive previous treatment for hepatitis C) Russian participants with genotype 1 chronic hepatitis C. After a screening period of approximately 4 weeks, participants will be treated for 12 weeks with telaprevir 750 mg every 8 hours in combination with Peg-IFN-alfa-2a and RBV followed by 12 or 36 weeks of treatment with Peg-IFN-alfa-2a and RBV alone depending on their liver disease status, response to previous treatment and individual virologic response during treatment in this study. After the treatment period, there is a follow-up phase of at least 12 weeks.

03

Conditions studied

  • Genotype 1 Chronic Hepatitis C

Browse trials for

Keywords

  • Genotype 1 chronic Hepatitis C
  • VX-950HPC3007
  • VX-950
  • Hepatitis C
  • Telaprevir
  • HCV
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has genotype 1 chronic with HCV RNA level >1000 IU/mL
  • Participant is either treatment-naïve and did not receive any previous treatment with any approved or drug or drug regimen for the treatment of hepatitis C, or participant is treatment-experienced who did not achieve sustained virologic response (SVR) 24 weeks after at least 1 prior course of Peg-IFN/RBV therapy (null-responder, partial-responder or viral relapse)
  • Participant must have documentation of liver or fibroscan within 2 years before the screening visit or agree to have a biopsy or fibroscan within the screening period unless histological cirrhosis was demonstrated by a biopsy or fibroscan > 2 years ago prior to screening
  • A female participant of and a nonvasectomized male participant who has a female partner of childbearing potential must agree to the use of 2 effective methods of from screening until 6 months (female participant ) or 7 months (male participant) after the last dose of RBV

Exclusion criteria

Exclusion Criteria:

  • Prior non-responder that is classified as a viral breakthrough participant
  • Participant is infected or co-infected with of another genotype than genotype 1
  • Participant has history of decompensated liver disease or shows evidence of significant liver disease in addition to hepatitis C
  • Participant has (HIV) or virus (HBV) co-infection
  • Participant has active malignant disease or history of malignant disease within the past 5 years (with the exception of treated basal cell carcinoma or hepatocellular carcinoma
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Treatment-naïve

    Treatment naïve participants will receive telaprevir 750 mg 8 hourly for 12 weeks in combination with Peg-IFN alfa-2a 180 microgram weekly and RBV 1000 - 1200 mg daily (dependent on weight) for 24 or 48 weeks. Total treatment duration will be based on participant's prior treatment status, liver disease status, and individual ontreatment virologic response in this study.

    Drug: Telaprevir · Drug: Pegylated-interferon-alfa-2a · Drug: Ribavirin

  • Experimental
    Treatment-experienced

    Treatment-experienced participants received telaprevir 750 mg 8 hourly for 12 weeks in combination with Peg-IFN alfa-2a 180 microgram weekly and RBV 1000 - 1200 mg daily (dependent on weight) for 24 or 48 weeks. Total treatment duration will be based on participant's prior treatment status, liver disease status, and individual on-treatment virologic response in this study.

    Drug: Telaprevir · Drug: Pegylated-interferon-alfa-2a · Drug: Ribavirin

Interventions

  • Telaprevir Type = exact number, unit = mg, number = 750, form = tablet, route = oral. Telaprevir 750 mg (2 oral tablets) is taken every 8 hours for 12 weeks

  • Pegylated-interferon-alfa-2a type = exact number, unit = microgram, number = 180, form = injection, route = subcutaneous. 180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks

  • Ribavirin Type = exact, number = 1000 or 1200, unit = mg, form = tablet, route = oral. 1000mg (if participant's weight is \< 75kg) or 1200mg (if participant's weight is \>= 75kg) per day for 24 or 48 weeks.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Extended Rapid Virologic Response (eRVR)

    A eRVR is defined as having hepatitis C virus (HCV) ribonucleic acid (RNA) less than 25 IU/mL, (target not detected) at Weeks 4 and 12 of treatment.

    Time frame: Week 4 and Week 12

Secondary outcomes

  1. Median Change in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)

    Changes from baseline in log10 HCV RNA levels were calculated.

    Time frame: Baseline (Week 0), Week 4, Week 8, Week 12, Week 24, Week 32, Week 40, and Week 48

  2. Number of Participants With Rapid Virologic Response (RVR) at Week 4

    A RVR is defined as having hepatitis C virus (HCV) ribonucleic acid (RNA) less than 25 IU/mL, (target not detected) at Week 4

    Time frame: Week 4

  3. Number of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Less Than 25 IU/mL, (Target Not Detected) at Weeks 8, 12, 24, 32, 40 and 48

    The table below shows number of participants with HCV RNA Less than 25 IU/mL, (target not detected) at Weeks 8, 12, 24, 32, 40 and 48. Only 3 treatment-naive and 14 Treatment-experienced participants were assigned to receive study treatment after Week 24. Only participants still receiving Treatment were assessed at 32, 40, and 48 weeks.

    Time frame: Weeks 8, 12, 24, 32, 40 and 48

  4. Number of Participants With Virologic Failure

    Virologic failure is defined as hepatitis C virus (HCV) ribonucleic acid (RNA) levels more than 1,000 IU/mL at Weeks 4, 8, 12, 24, 32, or 40.

    Time frame: Week 4, Week 8, Week 12, Week 24, Week 32, or Week 40

  5. Number of Participants in Each Specific Category of Treatment Outcome

    Participants were evaluated for following 4 categories of treatment outcome;Sustained Virologic Response 12 Weeks After Last Planned Dose of Study Medication(SVR12):hepatitis C virus (HCV)ribonucleic acid (RNA)\<25 IU/mL(target not detected)12 weeks after last planned dose of study medication;Relapse:HCV RNA =\>25 IU/mL during follow-up period after previous HCV RNA\<25 IU/mL at planned end of treatment(EOT)\[Week 24 or Week 48\] and participant did not achieve SVR12planned;On treatment virologic failure:meeting virologic stopping rule and/or having detectable HCV RNA at EOT with viral breakthrough(having a confirmed increase \>1 log 10 in HCV RNA level from the lowest level reached or confirmed value of HCV RNA \>100 IU/mL in participants whose HCV RNA has previously become \<25 IU/mL during treatment).Stopping rule defined as HCV RNA value \>1000 IU/mL at Week 4, 8 or 12 or detectable HCV RNA at Week 24, 32 or 40;Other:HCV RNA \<25 IU/mL at actual EOT and never HCV RNA =\>25 IU/mL thereafter.

    Time frame: From Day 1 (Baseline) up to Follow-up visit (Week 36 or Week 60)

07

Results

Posted Dec 30, 2013

Participant flow

The study was conducted at 5 sites in Russia.

Participant flow — Overall Study
MilestoneTreatment-naïveTreatment-experienced
Started1620
Completed1519
Not completed11
Withdrew: Withdrawal by subject11

Outcome measures

PrimaryNumber of Participants With Extended Rapid Virologic Response (eRVR)

A eRVR is defined as having hepatitis C virus (HCV) ribonucleic acid (RNA) less than 25 IU/mL, (target not detected) at Weeks 4 and 12 of treatment.

Time frame:
Week 4 and Week 12
Reported as:
Number · Participants
Number of Participants With Extended Rapid Virologic Response (eRVR)
ParticipantsTreatment-naïveTreatment-experienced
Number of Participants With Extended Rapid Virologic Response (eRVR)1318
SecondaryMedian Change in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)

Changes from baseline in log10 HCV RNA levels were calculated.

Time frame:
Baseline (Week 0), Week 4, Week 8, Week 12, Week 24, Week 32, Week 40, and Week 48
Reported as:
Median · Log 10 IU/mL
Median Change in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)
Log 10 IU/mLTreatment-naïveTreatment-experienced
Baseline (n=16, 20)6.20 (4.6 to 6.9)6.10 (5.7 to 7.0)
Week 4 (n=16, 20)-5.47 (-6.2 to -3.9)-5.33 (-6.3 to -3.5)
Week 8 (n=16,19)-5.50 (-6.2 to -3.9)-5.39 (-6.3 to -5.00)
Week 12 (n=15,19)-5.46 (-6.2 to -3.9)-5.39 (-6.3 to -5.00)
Week 24 (n=14, 19)-5.53 (-6.2 to -3.9)-5.39 (-6.3 to -0.6)
Week 32 (n=2, 12)-5.30 (-5.5 to -5.1)-5.46 (-6.3 to -5.2)
Week 40 (n=2, 12)-5.30 (-5.5 to -5.1)-5.46 (-6.3 to -5.2)
Week 48 (n=2, 12)-3.14 (-5.1 to -1.2)-5.46 (-6.3 to -5.2)
SecondaryNumber of Participants With Rapid Virologic Response (RVR) at Week 4

A RVR is defined as having hepatitis C virus (HCV) ribonucleic acid (RNA) less than 25 IU/mL, (target not detected) at Week 4

Time frame:
Week 4
Reported as:
Number · Participants
Number of Participants With Rapid Virologic Response (RVR) at Week 4
ParticipantsTreatment-naïveTreatment-experienced
Number of Participants With Rapid Virologic Response (RVR) at Week 41418
SecondaryNumber of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Less Than 25 IU/mL, (Target Not Detected) at Weeks 8, 12, 24, 32, 40 and 48

The table below shows number of participants with HCV RNA Less than 25 IU/mL, (target not detected) at Weeks 8, 12, 24, 32, 40 and 48. Only 3 treatment-naive and 14 Treatment-experienced participants were assigned to receive study treatment after Week 24. Only participants still receiving Treatment were assessed at 32, 40, and 48 weeks.

Time frame:
Weeks 8, 12, 24, 32, 40 and 48
Reported as:
Number · Participants
Number of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Less Than 25 IU/mL, (Target Not Detected) at Weeks 8, 12, 24, 32, 40 and 48
ParticipantsTreatment-naïveTreatment-experienced
Week 8 (n=16, 20)1619
Week 12 (n=16, 20)1519
Week 24 (n=16, 20)1518
Week 32 (n=3, 14)212
Week 40 (n=3, 14)212
Week 48 (n=3, 14)112
SecondaryNumber of Participants With Virologic Failure

Virologic failure is defined as hepatitis C virus (HCV) ribonucleic acid (RNA) levels more than 1,000 IU/mL at Weeks 4, 8, 12, 24, 32, or 40.

Time frame:
Week 4, Week 8, Week 12, Week 24, Week 32, or Week 40
Reported as:
Number · Participants
Number of Participants With Virologic Failure
ParticipantsTreatment-naïveTreatment-experienced
Number of Participants With Virologic Failure12
SecondaryNumber of Participants in Each Specific Category of Treatment Outcome

Participants were evaluated for following 4 categories of treatment outcome;Sustained Virologic Response 12 Weeks After Last Planned Dose of Study Medication(SVR12):hepatitis C virus (HCV)ribonucleic acid (RNA)\<25 IU/mL(target not detected)12 weeks after last planned dose of study medication;Relapse:HCV RNA =\>25 IU/mL during follow-up period after previous HCV RNA\<25 IU/mL at planned end of treatment(EOT)\[Week 24 or Week 48\] and participant did not achieve SVR12planned;On treatment virologic failure:meeting virologic stopping rule and/or having detectable HCV RNA at EOT with viral breakthrough(having a confirmed increase \>1 log 10 in HCV RNA level from the lowest level reached or confirmed value of HCV RNA \>100 IU/mL in participants whose HCV RNA has previously become \<25 IU/mL during treatment).Stopping rule defined as HCV RNA value \>1000 IU/mL at Week 4, 8 or 12 or detectable HCV RNA at Week 24, 32 or 40;Other:HCV RNA \<25 IU/mL at actual EOT and never HCV RNA =\>25 IU/mL thereafter.

Time frame:
From Day 1 (Baseline) up to Follow-up visit (Week 36 or Week 60)
Reported as:
Number · Participants
Number of Participants in Each Specific Category of Treatment Outcome
ParticipantsTreatment-naïveTreatment-experienced
SVR121416
Relapse01
On treatment virologic failure12
Other11

Adverse events

Collected over 60 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment-naïve—0/16 (0%)16/16 (100%)
Treatment-experienced—0/20 (0%)19/20 (95%)
Most frequent other events
Showing 10 of 18
Most frequent other events
EventTreatment-naïveTreatment-experienced
Influenza like illnessGeneral disorders6/169/20
PyrexiaGeneral disorders6/163/20
AnaemiaBlood and lymphatic system disorders6/166/20
AstheniaGeneral disorders5/163/20
PruritusSkin and subcutaneous tissue disorders4/162/20
RashSkin and subcutaneous tissue disorders4/160/20
NeutropeniaBlood and lymphatic system disorders2/164/20
CoughRespiratory, thoracic and mediastinal disorders3/160/20
ThrombocytopeniaBlood and lymphatic system disorders2/161/20
Alanine aminotransferase increasedInvestigations2/162/20

Baseline characteristics

Age, Customized
Age, Customized(Participants)Treatment-naïveTreatment-experiencedTotal
<= 45 years131225
Between 45 and 65 years2810
> 65 years101
Sex: Female, Male
Sex: Female, Male(Participants)Treatment-naïveTreatment-experiencedTotal
Female91322
Male7714
08

Study locations

5 sites
  • Moscow, Russian Federation
  • Saint-Petersburg, Russian Federation
  • Samara, Russian Federation
  • Smolensk, Russian Federation
  • Stavropol, Russian Federation
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Apr 2012 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2011
First posted
Dec 23, 2011
Start
Jan 2012
Primary completionActual
Apr 2012
CompletionActual
Mar 2013
Results first posted
Dec 30, 2013
Last update
Jan 30, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01498068
Responsible party
Sponsor
First posted
Dec 23, 2011
Start date
Jan 2012
Primary completion
Apr 2012
Completion
Mar 2013
Results posted
Dec 30, 2013
Last update
Jan 30, 2015

Study contacts

Janssen-Cilag International NV, Belgium Clinical Trial
study director · Janssen-Cilag International NV

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telaprevir · Peginterferon alfa-2a · Ribavirin

Start the discussion